Prima BioMed’s IMP321 is in clinical development for the treatment of a range of cancer indications. The company collaborates with pharmaceutical and biotech companies for its research and development activities. It has presence in Australia, Germany and France. Prima BioMed is headquartered in Sydney, New South Wales, Australia. 更多
